Dasatinib

Generic Name: Dasatinib

Brand Names: Sprycel

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₆ClN_₇O_₂S

CAS Number: 302962-49-8

Unique Ingredient Identifier: X78UG0A0RN

Background: Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication: Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Dasatinib
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2007-11-19

Last Posted Date: 2017-03-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT00560352

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States
🇪🇸
Local Institution, Salamanca, Spain

Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Dasatinib Maximum Tolerated Dose
Drug: Dasatinib

First Posted Date: 2007-10-30

Last Posted Date: 2023-09-26

Lead Sponsor: University of Nebraska

Target Recruit Count: 38

Registration Number: NCT00550615

Locations: 🇺🇸
University of Nebraska Medical Center, Internal Medicine Section of Oncology/Hematology, Omaha, Nebraska, United States

Phase II Dasatinib Study in Advanced Breast Cancer

Phase 2

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Dasatinib

First Posted Date: 2007-10-18

Last Posted Date: 2013-07-17

Lead Sponsor: Duke University

Target Recruit Count: 31

Registration Number: NCT00546104

Locations: 🇺🇸
Palm Beach Cancer Center Institute, West Palm Beach, Florida, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Presbyterian Health Care, Charlotte, North Carolina, United States

Dasatinib in Treating Patients With Stage IV Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: dasatinib
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: quality-of-life assessment

First Posted Date: 2007-10-16

Last Posted Date: 2015-10-05

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 7

Registration Number: NCT00544908

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
City of Hope Medical Group, Pasadena, California, United States

Dasatinib in Polycythemia Vera

Phase 2

Terminated

Conditions: Polycythemia Vera

Interventions: Drug: Dasatinib

First Posted Date: 2007-10-03

Last Posted Date: 2017-06-20

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 10

Registration Number: NCT00538980

Locations: 🇺🇸
Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
The Jones Clinic, Germantown, Tennessee, United States

and more 1 locations

Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2007-09-14

Last Posted Date: 2023-05-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 121

Registration Number: NCT00529763

Locations: 🇨🇳
Local Institution - 0004, Fuzhou, Fujian, China
🇨🇳
Local Institution - 0008, Suzhou, Jiangsu, China
🇨🇳
Local Institution, Hangzhou, Zhejiang, China

and more 1 locations

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Phase 2

Completed

Conditions: Malignant Mesothelioma

Interventions: Drug: dasatinib

First Posted Date: 2007-07-31

Last Posted Date: 2016-08-11

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 46

Registration Number: NCT00509041

Locations: 🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸
Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States
🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States

and more 34 locations

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Stage IV Squamous Cell Carcinoma of the Nasopharynx
Stage IVA Verrucous Carcinoma of the Larynx
Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Salivary Gland Squamous Cell Carcinoma
Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IVA Salivary Gland Cancer

Interventions: Drug: dasatinib
Procedure: pharmacological study
Procedure: laboratory biomarker analysis

First Posted Date: 2007-07-27

Last Posted Date: 2014-10-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00507767

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: dasatinib
Other: laboratory biomarker analysis

First Posted Date: 2007-07-19

Last Posted Date: 2014-05-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00504153

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-FU
Drug: Cetuximab
Drug: Dasatinib
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2007-07-16

Last Posted Date: 2019-08-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 86

Registration Number: NCT00501410

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy